NUVB Stock: Price, Earnings History and SEC Filings
Nuvation Bio Inc. (NUVB) last traded at $4.76, down 0.21% on the latest session and down 15.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.15 against an analyst estimate of $-0.15, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NUVB earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.15 | $-0.15 | +0.00% |
| Mar 2026 | May 4, 2026 | $0.01 | $0.12 | -91.67% |
| Dec 2025 | Mar 2, 2026 | $-0.11 | $-0.11 | +0.00% |
| Sep 2025 | Nov 3, 2025 | $-0.16 | $-0.17 | +5.88% |
NUVB beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How NUVB reacts to earnings
Across its last 8 earnings releases, NUVB moved 9.4% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | -4.08% |
| 2026-05-04 | After close | +9.52% |
| 2026-03-02 | After close | -25.34% |
| 2026-01-12 | Before open | -19.65% |
| 2025-11-03 | After close | -6.58% |
| 2025-08-07 | Before open | -0.43% |
| 2025-05-07 | After close | +2.94% |
| 2025-03-06 | After close | +6.88% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
NUVB financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $63M | -$205M | – | -325.3% | $-0.60 |
| 2024 | $8M | -$568M | – | -7213.8% | $-2.11 |
| 2023 | $0 | -$76M | – | – | $-0.35 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for NUVB
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Jul 6, 2026New financial obligation, Other events, Financial statements and exhibits
- 8-K · Jun 30, 2026Material agreement, Agreement terminated, New financial obligation
- 424B5 · Jun 29, 2026
- 424B5 · Jun 25, 2026
- 8-K · May 27, 2026Shareholder vote
- 8-K · May 4, 2026Results of operations, Financial statements and exhibits
- 10-Q · May 4, 2026
- DEF 14A · Apr 10, 2026
Insider filing activity
NUVB insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
NUVB news
- Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European CountriesOct 29, 2026 · finance.yahoo.com
- Nuvation Bio And 2 More Penny Stocks To WatchOct 24, 2026 · finance.yahoo.com
- Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026Oct 21, 2026 · finance.yahoo.com
About Nuvation Bio Inc.
Nuvation Bio Inc. (NUVB) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.